Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Shares of Valneva SE (NASDAQ:VALN) gapped up before the market opened on Tuesday . The stock had previously closed at $6.67, but opened at $7.40. Valneva shares last traded at $7.43, with a volume of 37,602 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Friday, January 31st.

Valneva Trading Up 9.9 %

The stock’s fifty day moving average price is $5.03 and its 200 day moving average price is $5.64. The stock has a market cap of $595.64 million, a P/E ratio of -56.38 and a beta of 1.98. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Investors Weigh In On Valneva

Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after buying an additional 29,748 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new position in Valneva during the fourth quarter valued at $84,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.